Future Outlook for Treatment of Endometrial Cancer
The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.
Ongoing Trials in Endometrial Cancer
An overview of ongoing research in the endometrial cancer treatment space.
KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer
A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.
NRG-GY018 and RUBY Trials in Endometrial Cancer
Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.
Recently Presented Data on Endometrial Cancer
The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.
MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer
Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.
Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer
A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.
Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Efficacy of Subsequent Therapies in Advanced Ovarian Cancer
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
Unmet Needs in the Maintenance Setting in Ovarian Cancer
An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.
Ovarian Cancer: Deciding Between Treatment Options
Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.
Frontline Maintenance Therapy in Ovarian Cancer
A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.
Dr. Salani on the Role of HER2 Expression in Advanced Uterine Serous Carcinoma
Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.
Dr. Salani on Updates in Treating Endometrial Cancer
Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.
Dr. Salani on the Role of Molecular Profiling in Endometrial Cancer Treatment
Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.
Dr. Salani on Future Research Opportunities in Recurrent Ovarian Cancer
Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.
Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer
Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.
Dr. Salani on the Potential Impact of Ongoing Research in Ovarian Cancer
Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.
Dr. Salani on Therapeutic Advances in Endometrial Cancer
Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.
Dr. Salani on the Current State of Biomarker Testing in Cervical Cancer
Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.
Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer
Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.
Dr. Salani on Choosing Among IV, IP, and Dose-Dense Chemo Regimens in Ovarian Cancer
Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.
Dr. Salani on the Progression of Upfront Ovarian Cancer Treatment
Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.
Dr. Salani on Patient Selection for Primary Debulking Surgery in Ovarian Cancer
Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.
Dr. Salani Discusses Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer
Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Dr. Salani Discusses Potential Treatment Modalities in Cervical Cancer
Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512